WADA prohibited list raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-31. Anything still debated is marked as such rather than presented as settled.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
To develop organisms with novel or enhanced characteristics, this emerging field of study combines biology, engineering, and related disciplines' knowledge and techniques to design chemically synthesized DNA. Biomolecular engineering includes approaches that aim to create a toolkit of functional units that can be introduced to present new technological functions in living cells. Genetic engineering includes approaches to construct synthetic chromosomes or minimal organisms like Mycoplasma laboratorium. Biomolecular design refers to the general idea of de novo design and additive combination of biomolecular components. Each of these approaches shares a similar task: to develop a more synthetic entity at a higher level of complexity by inventively manipulating a simpler part at the preceding level. Optimizing these exogenous pathways in unnatural systems takes iterative fine-tuning of the individual biomolecular components to select the highest concentrations of the desired product. On the other hand, "re-writers" are synthetic biologists interested in testing the irreducibility of biological systems. Due to the complexity of natural biological systems, it would be simpler to rebuild the natural systems of interest from the ground up; to provide engineered surrogates that are easier to comprehend, control and manipulate. Re-writers draw inspiration from refactoring, a process sometimes used to improve computer software.
Proteins are essential to life, performing many necessary cellular functions. Cells construct proteins with amino acids using DNA instructions. Typically, DNA is transcribed into messenger RNA (mRNA) and the mRNA is translated into a sequence of amino acids. The complex that facilitates translation from mRNA to amino acid is called the ribosome. Ribosomes hold and read mRNA in three nucleotide chunks called codons. Codons have a corresponding transport RNA (tRNA) that binds to the ribosome. tRNAs are responsible for bringing amino acids to the ribosome so they can be incorporated into the protein. Though each codon only codes for a single tRNA, a tRNA can represent multiple codons. This is because there are 64 possible codon combinations and 20 natural amino acids. Each tRNA codes for a single amino acid. Each amino acid is added to the growing chain of amino acids that will form the final protein. The initial chain of amino acids, also called the primary structure of the protein, determines the final shape and functional capacity of the protein.
Samples of water from the natural environment are routinely taken and analyzed as part of a pre-determined monitoring program by regulatory authorities to ensure that waters remain unpolluted, or if polluted, that the levels of pollution are not increasing or are falling in line with an agreed remediation plan. An example of such a scheme is the harmonized monitoring scheme operated on all the major river systems in the UK. The parameters analyzed will be highly dependent on nature of the local environment and/or the polluting sources in the area. In many cases the parameters will reflect the national and local water quality standards determined by law or other regulations. Typical parameters for ensuring that unpolluted surface waters remain within acceptable chemical standards include pH, major cations and anions including ammonia, nitrate, nitrite, phosphate, conductivity, phenol, chemical oxygen demand (COD) and biochemical oxygen demand (BOD).
In July 2020, the US National Institutes of Health stated "There is insufficient evidence to recommend for or against using vitamin D supplementation for the prevention or treatment of COVID-19." In that same year, the UK National Institute for Health and Care Excellence (NICE) position was to not recommend to offer a vitamin D supplement to people solely to prevent or treat COVID-19. NICE updated its position in 2022 to "Do not use vitamin D to treat COVID-19 except as part of a clinical trial." Both organizations included recommendations to continue the previously established recommendations on vitamin D supplementation for other reasons, such as bone and muscle health, as applicable. Both organizations noted that more people may require supplementation due to lower amounts of sun exposure during the pandemic. Vitamin D deficiency and insufficiency have been associated with adverse outcomes in COVID-19. Supplementation trials, mostly large, single, oral dose upon hospital admission, reported lower subsequent transfers to intensive care and to all-cause mortality.
=== War on cartels (2025–present) === The war on cartels is a hybridization of the war on terror and the war on drugs that describes the most aggressive and militarized phase of US foreign and security policy toward transnational criminal organizations, particularly active beginning in 2025 and into early 2026. Some analysts have noted that this war is moving away from previous paradigms of the war on drugs to become an official war. Unlike the law enforcement–centered efforts of previous decades, this phase is characterized by treating drug cartels not merely as ordinary criminal groups, but as national security threats equivalent to insurgent or terrorist organizations, thereby authorizing the use of high-level military capabilities. As a result, this strategy represents an operational and legal hybridization, as it merges the core objective of the war on drugs—the interdiction of narcotics flows and the dismantling of illicit economies—with the combat doctrine of the war on terror, shifting the paradigm from civilian law enforcement toward military counterinsurgency. By classifying these organizations as existential threats and narcoterrorist entities, the US legitimizes the use of tools traditionally reserved for enemy combatants, such as drone strikes, offensive cyber warfare, and extraterritorial special operations, including Operation Southern Spear, under the premise that cartels are no longer simple criminal groups to be arrested, but rather paramilitary structures that erode state sovereignty and require an asymmetric warfare response to be neutralized.
Sources: en.wikipedia.org
An important technique for characterizing metal carbonyls is infrared spectroscopy. The C–O vibration, typically denoted νCO, occurs at 2143 cm−1 for carbon monoxide gas. The energies of the νCO band for the metal carbonyls correlates with the strength of the carbon–oxygen bond, and inversely correlated with the strength of the π-backbonding between the metal and the carbon. The π-basicity of the metal center depends on a lot of factors; in the isoelectronic series (titanium to iron) at the bottom of this section, the hexacarbonyls show decreasing π-backbonding as one increases (makes more positive) the charge on the metal. π-Basic ligands increase π-electron density at the metal, and improved backbonding reduces νCO. The Tolman electronic parameter uses the Ni(CO)3 fragment to order ligands by their π-donating abilities. The number of vibrational modes of a metal carbonyl complex can be determined by group theory. Only vibrational modes that transform as the electric dipole operator will have nonzero direct products and are observed. The number of observable IR transitions (but not their energies) can thus be predicted. For example, the CO ligands of octahedral complexes, such as Cr(CO)6, transform as a1g, eg, and t1u, but only the t1u mode (antisymmetric stretch of the apical carbonyl ligands) is IR-allowed. Thus, only a single νCO band is observed in the IR spectra of the octahedral metal hexacarbonyls. Spectra for complexes of lower symmetry are more complex. For example, the IR spectrum of Fe2(CO)9 displays CO bands at 2082, 2019 and 1829 cm−1.
=== HIV/AIDS === Baricitinib has been investigated for its potential to reduce the HIV reservoir and chronic inflammation in people infected with HIV. Preclinical studies in humanized mice and non-human primates have demonstrated that the drug can penetrate the blood-brain barrier and reach therapeutic concentrations in the central nervous system (CNS). In these models, baricitinib was associated with a reduction in cellular activation markers, lower frequencies of infected macrophages in the brain, and improvements in HIV-associated behavioral deficits. Research suggests that by blocking the JAK-STAT signaling pathway, the drug may limit the survival of infected cells and prevent the reseeding of viral reservoirs in sanctuary sites like the CNS, which are often poorly reached by standard antiretroviral therapy (ART). As of 2025, baricitinib is currently being evaluated in multiple Phase II clinical trials to assess its safety and efficacy as an adjunctive therapy to ART. One primary area of focus is its ability to decrease or clear the CNS reservoir, with ongoing trials monitoring changes in cerebrospinal fluid (CSF) viral DNA and neurocognitive function. Additional studies are examining its impact on systemic inflammation, cell survival pathways, and the delay of viral rebound during monitored treatment interruptions.
27 May – First Minister Humza Yousaf accuses the UK government of sabotaging a pilot recycling scheme, the Deposit Return Scheme, by excluding glass from the project, glass having been a key part of Scottish proposals for the scheme. 31 May Thomas Henderson, who along with his co-accused, murdered a man during a botched robbery at the deceased man's Dundee flat, is sentenced to life prison ent th a minimum of 18 years. A huge wildfire covering 30 square miles (80 km2), possibly the largest ever seen in the UK, is brought under control by the Scottish Fire and Rescue Service at Cannich in the Highlands.
=== Other === The notochords in chordates are like the stomochords in hemichordates. Gastrotrichs, despite being in two different superphyla, resemble the kinorhynchids. Elvis taxa in the fossil record developed a similar morphology through convergent evolution. Venomous sting: to inject poison with a hypodermic needle, a sharp pointed tube, has shown up independently 10+ times: jellyfish, spiders, scorpions, centipedes, various insects, cone shell, snakes, some catfish, stingrays, stonefish, the male duckbill platypus, Siphonophorae and stinging nettles plant. Bioluminescence: symbiotic partnerships with light-emitting bacteria developed many times independently in deep-sea fish, jellyfish, fireflies, Rhagophthalmidae, Pyrophorus beetles, pyrosome, Mycena, Omphalotus nidiformis mushrooms, Vargula hilgendorfii, Quantula striata snail, googly-eyed glass squid, stiptic fungus, Noctiluca scintillans, Pyrocystis fusiformis, vargulin, sea pen, ostracod, Siphonophorae and glow worms. Bioluminescence is also produced by some animals directly. Parthenogenesis: Some lizards and insects have independent the capacity for females to produce live young from unfertilized eggs. Some species are entirely female. Several worm phyla have evolved an eversible proboscis, with examples being acanthocephalans, priapulids, kinorhynchs, and some polychaete worms. Extremely halophile archaeal family Halobacteriaceae and the extremely halophilic bacterium Salinibacter ruber both can live in high salt environment.
Yudin's 80,000-volume Russian library, the 1908 Schatz collection of early opera librettos, and the early 1930s purchase of the Russian Imperial Collection, consisting of 2,600 volumes from the library of the Romanov family on a variety of topics. Collections of Hebraica, Chinese, and Japanese works were also acquired. On one occasion, Congress initiated an acquisition: in 1929 Congressman Ross Collins (D-Mississippi) gained approval for the library to purchase Otto Vollbehr's collection of incunabula for $1.5 million. This collection included one of three remaining perfect vellum copies of the Gutenberg Bible.
Sources: en.wikipedia.org
Recently, a second parallel enzyme-dependent protective pathway was independently discovered by two labs that involves the oxidoreductase FSP1 (also known as AIFM2). FSP1 enzymatically reduces non-mitochondrial coenzyme Q10 (CoQ10), thereby generating a potent lipophilic antioxidant that suppresses the propagation of lipid peroxides. Vitamin K is also reduced by FSP1 to a hydroquinone species that also acts as a radical-trapping antioxidant and suppressor of ferroptosis. A similar mechanism for a cofactor moonlighting as a diffusable antioxidant was discovered in the same year for tetrahydrobiopterin (BH4), a product of the rate-limiting enzyme GTP cyclohydrolase 1 (GCH1). Hydropersulfides have been found to inhibit ferroptosis by acting as endogenous radical-trapping antioxidants.
==== Antipsychotics ==== Certain typical antipsychotics (first-generation) like chlorpromazine and atypical antipsychotics (second-generation) including clozapine, olanzapine, quetiapine, risperidone, ziprasidone, and zotepine may have sedative and/or hypnotic effects and have been used in the treatment of insomnia. However, the most commonly used agents for insomnia are quetiapine and olanzapine. They are thought to produce these effects via multiple mechanisms of action, including histamine H1 receptor antagonism, serotonin 5-HT2A receptor antagonism, α1-adrenergic receptor antagonism, and/or dopamine D2 receptor antagonism. While some of these drugs are frequently prescribed for insomnia, such use is not recommended unless the insomnia is due to an underlying mental health condition treatable by antipsychotics as the risks frequently outweigh the benefits. Some of the more serious adverse effects have been observed to occur at the low doses used for this off-label prescribing, such as dyslipidemia and neutropenia, and a recent network meta-analysis of 154 double-blind, randomized controlled trials of drug therapies vs. placebo for insomnia in adults found that quetiapine had not demonstrated any short-term benefits in sleep quality.
Yale University entered into its own licensing agreement with a private company, leading Fenn to file a lawsuit against the school in 1996. Yale countersued, requesting damages and reassignment of the patent. The two parties did not reach an out of court settlement, despite repeated attempts at mediation. In 2005, U.S. District Judge Christopher Droney ruled against Fenn, awarding Yale $545,000 in royalties and $500,000 in legal fees. Judge Droney was critical of Fenn, saying "Dr. Fenn only obtained the patent through fraud, civil theft, and breach of fiduciary duty." Evidence presented in the case indicated that Fenn had served on panels at Yale University that reviewed the institution's policy on intellectual property. A spokesperson for Yale said, "We are pleased by the result in this case and, in particular, by the court's vindication of the Yale patent policy." The ruling, and Yale's response produced a mixed reaction from some of Fenn's colleagues and former students, who wrote a letter to the Yale Daily News stating, "'Vindicating the Yale patent policy' is a poor excuse for treating a Nobel Laureate with a 68-year association with and dedicated service to the University, in such a contemptible manner."
"The One You Know" peaked at No. 9 on Billboard's Mainstream Rock chart. During an interview with Eddie Trunk on Trunk Nation on May 7, 2018, Jerry Cantrell said that the new album would be released at the end of August 2018. The band also revealed that they talked to director Adam Mason, who is making a dark sci-film, about doing two separate pieces of art and maybe molding them together, and that the music video for "The One You Know" is the first chapter of molding Mason's film and the band's music videos together. The second single, "So Far Under", was released on Alice in Chains' YouTube channel and on streaming platforms on June 27, 2018. It was also announced that the album would be titled Rainier Fog, with the release date scheduled for August 24, 2018. The album's artwork and the track listing were also revealed on the same day. Jerry Cantrell told Rolling Stone that the title Rainier Fog was inspired by the Mount Rainier in Seattle, and the title track is a tribute to the Seattle music scene. "This song is a little homage to all of that: where we come from, who we are, all of the triumphs, all of the tragedies, lives lived." The album's third single, "Never Fade", was released on August 10, 2018, through digital and streaming services. The song is a tribute dedicated to frontman William DuVall's grandmother, Chris Cornell, and Alice in Chains' original singer Layne Staley. "Never Fade" peaked at No. 10 on Billboard's Mainstream Rock chart.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.